GP
VBIV

GLG Partners’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

GLG Partners’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-484
Closed -$80K – 455
2017
Q1 		$80K Buy
+484
New +$65.5K ﹤0.01% 428

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GLG Partners's VBIV Position: Q2 2017 in Review

GLG Partners sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2017, closing a stake of 484 shares — an estimated $80K sold.

GLG Partners first reported a position in VBIV in Q1 2017 and held it in 1 quarter. The position peaked at $80K in Q1 2017. 37 funds tracked by Wall St. Rank hold VBIV as of Q2 2017.

  • GLG Partners reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2017 after selling out during the quarter.
  • GLG Partners sold 484 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2017, an estimated $80K.
  • GLG Partners first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2017 and held it in 1 quarter.
  • GLG Partners's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $80K in Q1 2017.
  • 37 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2017.

Based on GLG Partners's 13F filing for Q2 2017, filed 14 Aug 2017.